321 related articles for article (PubMed ID: 25586213)
1. Immunology, genetics and microbiota in the COPD pathophysiology: potential scope for patient stratification.
Malhotra R; Olsson H
Expert Rev Respir Med; 2015 Apr; 9(2):153-9. PubMed ID: 25586213
[TBL] [Abstract][Full Text] [Related]
2. Systemic Markers of Adaptive and Innate Immunity Are Associated with Chronic Obstructive Pulmonary Disease Severity and Spirometric Disease Progression.
Halper-Stromberg E; Yun JH; Parker MM; Singer RT; Gaggar A; Silverman EK; Leach S; Bowler RP; Castaldi PJ
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):500-509. PubMed ID: 29206476
[TBL] [Abstract][Full Text] [Related]
3. A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family.
Polverino F; Baraldo S; Bazzan E; Agostini S; Turato G; Lunardi F; Balestro E; Damin M; Papi A; Maestrelli P; Calabrese F; Saetta M
Am J Respir Crit Care Med; 2010 Oct; 182(8):1011-9. PubMed ID: 20581172
[TBL] [Abstract][Full Text] [Related]
4. Novel aspects of pathogenesis and regeneration mechanisms in COPD.
Bagdonas E; Raudoniute J; Bruzauskaite I; Aldonyte R
Int J Chron Obstruct Pulmon Dis; 2015; 10():995-1013. PubMed ID: 26082624
[TBL] [Abstract][Full Text] [Related]
5. The lung microbiome dynamics between stability and exacerbation in chronic obstructive pulmonary disease (COPD): Current perspectives.
Dima E; Kyriakoudi A; Kaponi M; Vasileiadis I; Stamou P; Koutsoukou A; Koulouris NG; Rovina N
Respir Med; 2019 Oct; 157():1-6. PubMed ID: 31450162
[TBL] [Abstract][Full Text] [Related]
6. Do frequent moderate exacerbations contribute to progression of chronic obstructive pulmonary disease in patients who are ex-smokers?
Dreyse J; Díaz O; Repetto PB; Morales A; Saldías F; Lisboa C
Int J Chron Obstruct Pulmon Dis; 2015; 10():525-33. PubMed ID: 25792820
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of altered cell immunity and cytotoxicity in COPD.
Tsoumakidou M; Tsiligianni I; Tzanakis N
Curr Drug Targets; 2011 Apr; 12(4):450-9. PubMed ID: 21194409
[TBL] [Abstract][Full Text] [Related]
8. Is TNF-α gene polymorphism related to pulmonary functions and prognosis as determined by FEV1, BMI, COPD exacerbation and hospitalization in patients with smoking-related COPD in a Turkish population?
Özdoğan N; Tutar N; Demir R; Saatçi Ç; Kanbay A; Büyükoğlan H
Rev Port Pneumol; 2014; 20(6):305-10. PubMed ID: 24818527
[TBL] [Abstract][Full Text] [Related]
9. Bacterial microbiome of lungs in COPD.
Sze MA; Hogg JC; Sin DD
Int J Chron Obstruct Pulmon Dis; 2014; 9():229-38. PubMed ID: 24591822
[TBL] [Abstract][Full Text] [Related]
10. Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: findings from the lung health study.
Tashkin DP; Rabinoff M; Noble EP; Ritchie TL; Simmons MS; Connett J
COPD; 2012 Dec; 9(6):620-8. PubMed ID: 22958175
[TBL] [Abstract][Full Text] [Related]
11. The pathology of chronic obstructive pulmonary disease.
Hogg JC; Timens W
Annu Rev Pathol; 2009; 4():435-59. PubMed ID: 18954287
[TBL] [Abstract][Full Text] [Related]
12. New insights into the immunology of chronic obstructive pulmonary disease.
Brusselle GG; Joos GF; Bracke KR
Lancet; 2011 Sep; 378(9795):1015-26. PubMed ID: 21907865
[TBL] [Abstract][Full Text] [Related]
13. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers.
Löfdahl JM; Wahlström J; Sköld CM
Clin Exp Immunol; 2006 Sep; 145(3):428-37. PubMed ID: 16907910
[TBL] [Abstract][Full Text] [Related]
14. Immune and genetic mechanisms in COPD: possible targets for therapeutic interventions.
Tzortzaki EG; Papi A; Neofytou E; Soulitzis N; Siafakas NM
Curr Drug Targets; 2013 Feb; 14(2):141-8. PubMed ID: 23256714
[TBL] [Abstract][Full Text] [Related]
15. Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD.
Van Pottelberge GR; Bracke KR; Demedts IK; De Rijck K; Reinartz SM; van Drunen CM; Verleden GM; Vermassen FE; Joos GF; Brusselle GG
Respir Res; 2010 Mar; 11(1):35. PubMed ID: 20307269
[TBL] [Abstract][Full Text] [Related]
16. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer.
Brody JS; Spira A
Proc Am Thorac Soc; 2006 Aug; 3(6):535-7. PubMed ID: 16921139
[TBL] [Abstract][Full Text] [Related]
17. Evasion of COPD in smokers: at what price?
Cosio MG; Saetta M
Eur Respir J; 2012 Jun; 39(6):1298-303. PubMed ID: 22005915
[TBL] [Abstract][Full Text] [Related]
18. Chronic obstructive pulmonary disease and lung cancer: new molecular insights.
Adcock IM; Caramori G; Barnes PJ
Respiration; 2011; 81(4):265-84. PubMed ID: 21430413
[TBL] [Abstract][Full Text] [Related]
19. Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease.
Seys LJ; Verhamme FM; Schinwald A; Hammad H; Cunoosamy DM; Bantsimba-Malanda C; Sabirsh A; McCall E; Flavell L; Herbst R; Provoost S; Lambrecht BN; Joos GF; Brusselle GG; Bracke KR
Am J Respir Crit Care Med; 2015 Sep; 192(6):706-18. PubMed ID: 26266827
[TBL] [Abstract][Full Text] [Related]
20. Genetic predisposition to chronic obstructive pulmonary disease and/or lung cancer: important considerations when evaluating risk.
El-Zein RA; Young RP; Hopkins RJ; Etzel CJ
Cancer Prev Res (Phila); 2012 Apr; 5(4):522-7. PubMed ID: 22491518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
